Ependymoma Medication

1. Hübner JM, Kool M, Pfister SM, Pajtler KW. Epidemiology, molecular classification and WHO grading of ependymoma. J Neurosurg Sci. 2018 Feb. 62 (1):46-50. [QxMD MEDLINE Link]. [Full Text].

2. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun. 131 (6):803-20. [QxMD MEDLINE Link].

3. Verma A, Zhou H, Chin S, Bruggers C, Kestle J, Khatua S. EGFR as a predictor of relapse in myxopapillary ependymoma. Pediatr Blood Cancer. 2011 Dec 20. [QxMD MEDLINE Link].

4. Tripathy P, Mohapatra D, Mohapatra S. Primary intradural extramedullary ependymoma: report of two cases and review of the literature. Neurol Neurochir Pol. 2011 Jul-Aug. 45(4):397-401. [QxMD MEDLINE Link].

5. Costa FF, Bischof JM, Vanin EF, Lulla RR, Wang M, Sredni ST, et al. Identification of microRNAs as potential prognostic markers in ependymoma. PLoS One. 2011. 6(10):e25114. [QxMD MEDLINE Link]. [Full Text].

6. Son DW, Song GS, Han IH, Choi BK. Primary extramedullary ependymoma of the cervical spine : case report and review of the literature. J Korean Neurosurg Soc. 2011 Jul. 50(1):57-9. [QxMD MEDLINE Link]. [Full Text].

7. Chamberlain MC, Kormanik PA. Practical guidelines for the treatment of malignant gliomas. West J Med. 1998 Feb. 168(2):114-20. [QxMD MEDLINE Link].

8. Merchant TE. Current management of childhood ependymoma. Oncology (Williston Park). 2002/05. 16(5):629-42, 644; discussion 645-6, 648.

9. [Guideline] National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology: Central Nervous System Cancers. NCCN. Available at http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Version 1.2021 — June 4, 2021; Accessed: July 3, 2021.

10. Timmermann B, Kortmann RD, Kühl J, Meisner C, Slavc I, Pietsch T. Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood: results of the German prospective trials HIT 88/89 and HIT 91. Int J Radiat Oncol Biol Phys. 2000 Jan 15. 46(2):287-95. [QxMD MEDLINE Link].

11. Applegate GL, Marymont MH. Intracranial ependymomas: a review. Cancer Invest. 1998. 16(8):588-93. [QxMD MEDLINE Link].

12. Schwartz TH, Kim S, Glick RS, et al. Supratentorial ependymomas in adult patients. Neurosurgery. 1999 Apr. 44(4):721-31. [QxMD MEDLINE Link].

13. Poppleton H, Gilbertson RJ. Stem cells of ependymoma. Br J Cancer. 2007 Jan 15. 96(1):6-10. [QxMD MEDLINE Link].

14. Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P, et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell. 2005 Oct. 8(4):323-35. [QxMD MEDLINE Link].

15. Dal Cin P, Sandberg AA. Cytogenetic findings in a supratentorial ependymoma. Cancer Genet Cytogenet. 1988 Feb. 30(2):289-93. [QxMD MEDLINE Link].

16. Metzger AK, Sheffield VC, Duyk G, et al. Identification of a germ-line mutation in the p53 gene in a patient with an intracranial ependymoma. Proc Natl Acad Sci U S A. 1991 Sep 1. 88(17):7825-9. [QxMD MEDLINE Link].

17. Sainati L, Montaldi A, Putti MC, et al. Cytogenetic t(11;17)(q13;q21) in a pediatric ependymoma. Is 11q13 a recurring breakpoint in ependymomas?. Cancer Genet Cytogenet. 1992 Apr. 59(2):213-6. [QxMD MEDLINE Link].

18. Mazewski C, Soukup S, Ballard E, et al. Karyotype studies in 18 ependymomas with literature review of 107 cases. Cancer Genet Cytogenet. 1999 Aug. 113(1):1-8. [QxMD MEDLINE Link].

19. Nijssen PC, Deprez RH, Tijssen CC, et al. Familial anaplastic ependymoma: evidence of loss of chromosome 22 in tumour cells. J Neurol Neurosurg Psychiatry. 1994 Oct. 57(10):1245-8. [QxMD MEDLINE Link].

20. Yokota T, Tachizawa T, Fukino K, Teramoto A, Kouno J, Matsumoto K. A family with spinal anaplastic ependymoma: evidence of loss of chromosome 22q in tumor. J Hum Genet. 2003. 48(11):598-602. [QxMD MEDLINE Link].

21. Ebert C, von Haken M, Meyer-Puttlitz B, et al. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol. 1999 Aug. 155(2):627-32. [QxMD MEDLINE Link].

22. Hulsebos TJ, Oskam NT, Bijleveld EH, Westerveld A, Hermsen MA, van den Ouweland AM. Evidence for an ependymoma tumour suppressor gene in chromosome region 22pter-22q11.2. Br J Cancer. 1999 Dec. 81(7):1150-4. [QxMD MEDLINE Link].

23. James CD, He J, Carlbom E, et al. Loss of genetic information in central nervous system tumors common to children and young adults. Genes Chromosomes Cancer. 1990 Jul. 2(2):94-102. [QxMD MEDLINE Link].

24. Yao Y, Mack SC, Taylor MD. Molecular genetics of ependymoma. Chin J Cancer. 2011 Oct. 30(10):669-81. [QxMD MEDLINE Link].

25. Mack SC, Pajtler KW, Chavez L, Okonechnikov K, Bertrand KC, et al. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature. 2018 Jan 4. 553 (7686):101-105. [QxMD MEDLINE Link].

26. Cavalli FMG, Hübner JM, Sharma T, et al. Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathol. 2018 Aug. 136 (2):227-237. [QxMD MEDLINE Link]. [Full Text].

27. Pajtler KW, Witt H, Sill M, et al. Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell. 2015 May 11. 27 (5):728-43. [QxMD MEDLINE Link]. [Full Text].

28. Jung TY, Jung S, Kook H, Baek HJ. Treatment Decisions of World Health Organization Grade II and III Ependymomas in Molecular Era. J Korean Neurosurg Soc. 2018 May. 61 (3):312-318. [QxMD MEDLINE Link]. [Full Text].

29. Raffeld M, Abdullaev Z, Pack SD, Xi L, Nagaraj S, Briceno N, et al. High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma. Acta Neuropathol Commun. 2020 Jul 8. 8 (1):101. [QxMD MEDLINE Link]. [Full Text].

30. McGuire CS, Sainani KL, Fisher PG. Incidence patterns for ependymoma: a Surveillance, Epidemiology, and End Results study. J Neurosurg. 2008 Dec 5. [QxMD MEDLINE Link].

31. Polednak AP, Flannery JT. Brain, other central nervous system, and eye cancer. Cancer. 1995 Jan 1. 75(1 Suppl):330-7. [QxMD MEDLINE Link].

32. Healey EA, Barnes PD, Kupsky WJ, Scott RM, Sallan SE, Black PM. The prognostic significance of postoperative residual tumor in ependymoma. Neurosurgery. 1991 May. 28(5):666-71; discussion 671-2. [QxMD MEDLINE Link].

33. Carrie C, Mottolese C, Bouffet E, Negrier S, Bachelot TH, Lasset C. Non-metastatic childhood ependymomas. Radiother Oncol. 1995 Aug. 36(2):101-6. [QxMD MEDLINE Link].

34. McGuire CS, Sainani KL, Fisher PG. Both location and age predict survival in ependymoma: a SEER study. Pediatr Blood Cancer. 2009 Jan. 52(1):65-9. [QxMD MEDLINE Link].

35. Chiu JK, Woo SY, Ater J, et al. Intracranial ependymoma in children: analysis of prognostic factors. J Neurooncol. 1992 Jul. 13(3):283-90. [QxMD MEDLINE Link].

36. Amirian ES, Armstrong TS, Gilbert MR, Scheurer ME. Predictors of survival among older adults with ependymoma. J Neurooncol. 2011 Sep 28. [QxMD MEDLINE Link].

37. Tomita T, McLone DG, Das L, Brand WN. Benign ependymomas of the posterior fossa in childhood. Pediatr Neurosci. 1988. 14(6):277-85. [QxMD MEDLINE Link].

38. Sutton LN, Goldwein J, Perilongo G, Lang B, Schut L, Rorke L. Prognostic factors in childhood ependymomas. Pediatr Neurosurg. 1990-1991. 16(2):57-65. [QxMD MEDLINE Link].

39. Jayawickreme DP, Hayward RD, Harkness WF. Intracranial ependymomas in childhood: a report of 24 cases followed for 5 years. Childs Nerv Syst. 1995 Jul. 11(7):409-13. [QxMD MEDLINE Link].

40. Pollack IF, Gerszten PC, Martinez AJ, et al. Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery. 1995 Oct. 37(4):655-66; discussion 666-7. [QxMD MEDLINE Link].

41. Robertson PL, Zeltzer PM, Boyett JM, et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg. 1998 Apr. 88(4):695-703. [QxMD MEDLINE Link].

42. Horn B, Heideman R, Geyer R, Pollack I, Packer R, Goldwein J. A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. J Pediatr Hematol Oncol. 1999 May-Jun. 21(3):203-11. [QxMD MEDLINE Link].

43. Merchant TE, Mulhern RK, Krasin MJ, Kun LE, Williams T, Li C. Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol. 2004 Aug 1. 22(15):3156-62. [QxMD MEDLINE Link].

44. Bouffet E, Perilongo G, Canete A, Massimino M. Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol. 1998 Jun. 30(6):319-29; discussion 329-31. [QxMD MEDLINE Link].

45. Macdonald J. Advances in imaging techniques in neuroendocrine tumors: miscellaneous papers of interest. Curr Opin Oncol. 1990 Feb. 2(1):117-8. [QxMD MEDLINE Link].

46. Rogers L, Pueschel J, Spetzler R, et al. Is gross-total resection sufficient treatment for posterior fossa ependymomas?. J Neurosurg. 2005 Apr. 102(4):629-36. [QxMD MEDLINE Link].

47. Merchant TE, Li C, Xiong X, Gaber MW. Cytokine and Growth Factor Responses After Radiotherapy for Localized Ependymoma. Int J Radiat Oncol Biol Phys. 2008 Nov 17. [QxMD MEDLINE Link].

48. Leroy R, Benahmed N, Hulstaert F, Van Damme N, De Ruysscher D. Proton Therapy in Children: A Systematic Review of Clinical Effectiveness in 15 Pediatric Cancers. Int J Radiat Oncol Biol Phys. 2016 May 1. 95 (1):267-78. [QxMD MEDLINE Link].

49. Goldwein JW, Glauser TA, Packer RJ, et al. Recurrent intracranial ependymomas in children. Survival, patterns of failure, and prognostic factors. Cancer. 1990 Aug 1. 66(3):557-63. [QxMD MEDLINE Link].

50. Stafford SL, Pollock BE, Foote RL, Gorman DA, Nelson DF, Schomberg PJ. Stereotactic radiosurgery for recurrent ependymoma. Cancer. 2000 Feb 15. 88(4):870-5. [QxMD MEDLINE Link].

51. Agbahiwe HC, Wharam M, Batra S, Cohen K, Terezakis SA. Management of pediatric myxopapillary ependymoma: the role of adjuvant radiation. Int J Radiat Oncol Biol Phys. 2013 Feb 1. 85(2):421-7. [QxMD MEDLINE Link].

52. Fujiwara Y, Manabe H, Izumi B, Shima T, Adachi N. Remarkable efficacy of temozolomide for relapsed spinal myxopapillary ependymoma with multiple recurrence and cerebrospinal dissemination: a case report and literature review. Eur Spine J. 2017 Dec 21. [QxMD MEDLINE Link].

53. Partap S, Fisher PG. Update on new treatments and developments in childhood brain tumors. Curr Opin Pediatr. 2007 Dec. 19(6):670-4. [QxMD MEDLINE Link].

54. Reni M, Gatta G, Mazza E, Vecht C. Ependymoma. Crit Rev Oncol Hematol. 2007 Jul. 63(1):81-9. [QxMD MEDLINE Link].

55. Tabori U, Ma J, Carter M, Zielenska M, Rutka J, Bouffet E, et al. Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J Clin Oncol. 2006 Apr 1. 24(10):1522-8. [QxMD MEDLINE Link].

56. Sowar K, Straessle J, Donson AM, Handler M, Foreman NK. Predicting which children are at risk for ependymoma relapse. J Neurooncol. 2006 May. 78(1):41-6. [QxMD MEDLINE Link].

57. Modena P, Lualdi E, Facchinetti F, Veltman J, Reid JF, Minardi S, et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol. 2006 Nov 20. 24(33):5223-33. [QxMD MEDLINE Link].

58. Catsman-Berrevoets CE, Van Dongen HR, Mulder PG, et al. Tumour type and size are high risk factors for the syndrome of "cerebellar" mutism and subsequent dysarthria. J Neurol Neurosurg Psychiatry. 1999 Dec. 67(6):755-7. [QxMD MEDLINE Link].

59. Doxey D, Bruce D, Sklar F, et al. Posterior fossa syndrome: identifiable risk factors and irreversible complications. Pediatr Neurosurg. 1999 Sep. 31(3):131-6. [QxMD MEDLINE Link].

Jeffrey N Bruce, MD Edgar M Housepian Professor of Neurological Surgery Research, Vice-Chairman and Professor of Neurological Surgery, Director of Brain Tumor Tissue Bank, Director of Bartoli Brain Tumor Laboratory, Department of Neurosurgery, Columbia University College of Physicians and Surgeons

Jeffrey N Bruce, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for the Advancement of Science, American Association of Neurological Surgeons, American Society of Clinical Oncology, Congress of Neurological Surgeons, New York Academy of Sciences, North American Skull Base Society, Pituitary Society, Society for Neuro-Oncology, Society of Neurological Surgeons

Disclosure: Received grant/research funds from NIH for other.

David J Fusco, MD Associate Neurosurgeon, Barrow Neurosurgical Associates

David J Fusco, MD is a member of the following medical societies: American Association of Neurological Surgeons, American Medical Association, North American Spine Society, Congress of Neurological Surgeons

Disclosure: Nothing to disclose.

Neil A Feldstein, MD Director of Pediatric Neurosurgery, Department of Neurosurgery, Babies and Children's Hospital of New York, Assistant Professor,Departments of Clinical Neurosurgery and Pediatrics, Columbia-Presbyterian Medical Center, Columbia University

Neil A Feldstein, MD is a member of the following medical societies: American Association of Neurological Surgeons, American Cleft Palate-Craniofacial Association, American College of Surgeons, American Medical Association, Medical Society of the State of New York

Disclosure: Nothing to disclose.

Benjamin C Kennedy, MD Assistant Professor of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania; Director of Epilepsy and Functional Neurosurgery, The Children’s Hospital of Philadelphia

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Herbert H Engelhard, III, MD, PhD, FACS, FAANS Affiliated Professor of Bioengineering, University of Illinois at Chicago

Herbert H Engelhard, III, MD, PhD, FACS, FAANS is a member of the following medical societies: American Association for Cancer Research, American Association of Neurological Surgeons, American College of Surgeons, American Medical Association, Congress of Neurological Surgeons, Illinois State Medical Society

Disclosure: Nothing to disclose.

Robert C Shepard, MD, FACP Associate Professor of Medicine in Hematology and Oncology at University of North Carolina at Chapel Hill; Vice President of Scientific Affairs, Therapeutic Expertise, Oncology, at PRA International

Robert C Shepard, MD, FACP is a member of the following medical societies: American Association for Cancer Research, American Association for Physician Leadership, European Society for Medical Oncology, Association of Clinical Research Professionals, American Federation for Clinical Research, Eastern Cooperative Oncology Group, Society for Immunotherapy of Cancer, American Medical Informatics Association, American College of Physicians, American Federation for Medical Research, American Medical Association, American Society of Hematology, Massachusetts Medical Society

Disclosure: Nothing to disclose.

We wish to acknowledge previous contributions to this article by Paul C McCormick, MD, and Allen Waziri, MD.

• Print this section
• Print the entire contents of
• Print the entire contents of article